Literature DB >> 5002313

Therapy of staphylococcal infections in monkeys. VII. Comparison of cyclacillin and nafcillin.

H N Carlisle, S Saslaw.   

Abstract

Intravenous inoculation of a penicillin-resistant phage type 80/81 staphylococcus caused lethal infection in seven of eight untreated monkeys. Daily intragastric administration of 50 mg/kg given in two equal morning and afternoon doses of cyclacillin and nafcillin was followed by mortalities of four of four and two of four monkeys, respectively. After 100 mg per kg per day, three of four and one of four monkeys receiving cyclacillin and nafcillin, respectively, died. Thus, mortality in controls and cyclacillin-treated monkeys was seven of eight as compared to three of eight after nafcillin treatment. Although the staphylococcus was more resistant to cyclacillin (minimal inhibitory concentration = 7.80 mug/ml) than to nafcillin (minimal inhibitory concentration = 0.31 mug/ml), regular rapid absorption and high levels of the former suggested potential efficacy. However, the similar mortality in cyclacillin-treated and control monkeys indicated that the in vitro data did not, in this instance, conform to the in vivo observations.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5002313      PMCID: PMC376436          DOI: 10.1128/am.22.5.865-869.1971

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  11 in total

1.  Studies of therapy of staphylococcal infections in monkeys. II. Comparison of cloxacillin, dicloxacillin, and leucomycin.

Authors:  S Saslaw; H N Carlisle
Journal:  Proc Soc Exp Biol Med       Date:  1968-06

2.  Studies on therapy of staphylococcal infections in monkeys. I. Comparison of cloxacillin, triacetyloleandomycin and erythromycin.

Authors:  S Saslaw; H N Carlisle
Journal:  Proc Soc Exp Biol Med       Date:  1967 Aug-Sep

3.  Staphylococcal infection in normal and splenectomized monkeys.

Authors:  S Saslaw; H N Carlisle
Journal:  Proc Soc Exp Biol Med       Date:  1966-11

4.  Studies on therapy of staphylococcal infections in monkeys. 3. Comparison of cephalothin, cephaloridine and cephalexin.

Authors:  S Saslaw; H N Carlisle
Journal:  Am J Med Sci       Date:  1968-09       Impact factor: 2.378

5.  Cephalexin: in vitro bacterial susceptibility, absorption in volunteers, and antibacterial activity of sera and urine.

Authors:  R L Perkins; H N Carlisle; S Saslaw
Journal:  Am J Med Sci       Date:  1968-08       Impact factor: 2.378

6.  Antimicrobial activity and pharmacological distribution of Wy-4508, an aminoalicyclic penicillin.

Authors:  S B Roseman; L S Weber; G Owen; G H Warren
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

7.  Duration of therapeutic activity of aminoalicyclic penicillins against bacterial infections in mice.

Authors:  M W Hopper; J A Yurchenco; G H Warren
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

8.  Studies on therapy of staphylococcal infections in monkeys. V. Comparison of cephalexin, oxacillin, cloxacillin, dicloxacillin and nafcillin.

Authors:  S Saslaw; H N Carlisle; J Sparks
Journal:  Am J Med Sci       Date:  1970-02       Impact factor: 2.378

9.  Therapy of staphylococcal infections in monkeys. IV. Further comparison of triacetyloleandomycin and erythromycins.

Authors:  S Saslaw; H N Carlisle; M Marietti
Journal:  Appl Microbiol       Date:  1969-12

10.  Therapy of staphylococcal infections in monkeys. VI. Comparison of clindamycin, erythromycin, and methicillin.

Authors:  H N Carlisle; S Saslaw
Journal:  Appl Microbiol       Date:  1971-03
View more
  2 in total

1.  [Principles for the therapy of bacterial bronchopulmonary diseases].

Authors:  G Mössner; W Quarz
Journal:  Infection       Date:  1973       Impact factor: 3.553

2.  Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk.

Authors:  Nicos Fotiadis; Katja N De Paepe; Lawrence Bonne; Nasir Khan; Angela Riddell; Nicholas Turner; Naureen Starling; Marco Gerlinger; Sheela Rao; Ian Chau; David Cunningham; Dow-Mu Koh
Journal:  Eur Radiol       Date:  2020-07-14       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.